Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models
- 1 February 2019
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 442, 82-90
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (U01CA175315)
- National Institute of General Medical Sciences, National Institutes of Health (R01GM113888)
- 111 Project (B16047)
- National key research and development program (2017YFE0109900)
- National Cancer Institute (NCI P30CA093373)
This publication has 44 references indexed in Scilit:
- ARID3B Induces Tumor Necrosis Factor Alpha Mediated Apoptosis While a Novel ARID3B Splice Form Does Not Induce Cell DeathPLOS ONE, 2012
- Patient-derived tumour xenografts as models for oncology drug developmentNature Reviews Clinical Oncology, 2012
- Posttranscriptional Upregulation by MicroRNAsWIREs RNA, 2011
- Pancreatic CancerNew England Journal of Medicine, 2010
- ARID3B Induces Malignant Transformation of Mouse Embryonic Fibroblasts and Is Strongly Associated with Malignant NeuroblastomaCancer Research, 2006
- An In vivo Platform for Translational Drug Development in Pancreatic CancerClinical Cancer Research, 2006
- The functions of animal microRNAsNature, 2004
- MicroRNAsCell, 2004
- Human pancreatic adenocarcinoma: In vitro and in vivo morphology of a new tumor line established from ascitesIn Vitro Cellular & Developmental Biology - Plant, 1982
- Establishment of a continuous tumor‐cell line (PANC‐1) from a human carcinoma of the exocrine pancreasInternational Journal of Cancer, 1975